Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

Clinical and Translational Science

Volumn 10, Issue 3, 2017, Pages 194-200

  Pai, A B ^a   Meyer, D E ^b   Bales, B C ^b   Cotero, V E ^b   Pai, M P ^a   Zheng, N ^c   Jiang, W ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GE GLOBAL RESEARCH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESFERROXIMINE; FERRIC GLUCONATE; FERUMOXYTOL; GE 121333; IRON CHELATING AGENT; IRON SACCHARATE; UNCLASSIFIED DRUG; BLEOMYCIN; IRON;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; NONHUMAN; OXIDATION REDUCTION REACTION; RAT; ANIMAL; BIOASSAY; CALIBRATION; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIOLOGICAL ASSAY; BLEOMYCIN; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IRON; IRON CHELATING AGENTS; OXIDATION-REDUCTION; RATS;

EID: 85012883197     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12443     Document Type: Article

References (27)

1. Charytan, D.M. et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 26, 1238–1247 (2015).
2. Danielson, B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am Soc. Nephrol. 15, S93–S98 (2004).
3. Jahn, M.R. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78, 480–491 (2011).
4. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 8, 2101–2141 (2011).
5. Yang, Y., Shah, R.B., Faustino, P.J., Raw, A., Yu, L.X. & Khan, M.A. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J. Pharm. Sci. 99, 142–153 (2010).
6. Pai, A.B., Boyd, A.V., McQuade, C.R., Harford, A., Norenberg, J.P. & Zager, P.G. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and sucrose in patients undergoing hemodialysis. Pharmacotherapy 27, 343–350 (2007).
7. Balakrishnan, V.S. et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39, 489–496 (2009).
8. Toblli, J.E., Cao, G., Oliveri, L. & Angerosa, M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy Drug Targets 11, 66–78 (2012).
9. Stein, J., Dignass, A. & Chow, K.U. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 28, 241–243 (2012).
10. Kuo, K.L., Hung, S.C., Lee, T.S. & Tarng, D.C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J. Am Soc. Nephrol. 25, 2596–2606 (2014).
11. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/078215s000ltr.pdf accessed 6_1_16
12. https://www.drugs.com/pro/nulecit.html accessed 6_1_16
13. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358142.pdf accessed 6_1_16
14. Shi, Q. et al. Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses. Contrast Media Mol. Imaging 8, 281–288 (2013).
15. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. & Cabantchik, Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670–2677 (2003).
16. Burkitt, M.J., Milne, L. & Raafat, A. A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the ‘catalytic iron index’ and its value in the assessment of iron status in haemochromatosis. Clin. Sci. (Lond). 100, 239–247 (2001).
17. Breuer, W., Ermers, M.J.J., Pootrakul, P., Abramov, A., Hersko, C. & Cabantchik, Z.I. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97, 792–789 (2001).
18. Su, B.L. et al. Fl-DFO molecules mesoporous silica materials: highly sensitive and selective nanosensor for dosing with iron ions. J. Colloid Interface Sci. 358, 136–145 (2011).
19. Tesoro, A., Novakovic, J., Thiessen, J.J. & Spino, M. Validated HPLC assay for iron determination in biological matrices based on ferrioxamine formation. J. Chromatogr. Analyt. Technol. Biomed. Life Sci. 823, 177–183 (2005).
20. Koba, M., Słomka, A., Bączek, T., Marszałł, M.P. & Zekanowska, E. Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPL. J. Sep. Sci. 36, 665–669 (2013).
21. European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf. Accessed 6_1_16 (2011)
22. Cabantchik, Z.I. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front. Pharmacol. 13, 45 (2014).
23. Brookhart, M.A., Freburger, J.K., Ellis, A.R., Wang, L., Winkelmayer, W.C. & Kshirsagar, A.V. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J. Am. Soc. Nephrol. 24, 1151–1158 (2013).
24. Lee, E.S., Park, B.R., Kim, J.S., Choi, G.Y., Lee, J.J. & Lee, I.S. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 29, 141–147 (2013).
25. Seligman, P.A. et al. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 24, 574–583 (2004).
26. Onken, J.E. et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol. Dial. Transplant. 29, 833–842 (2014).
27. Breuer, W., Ronson, A., Slotki, I.N., Abramov, A., Hershko, C. & Cabantchik, Z.I. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95, 2975–2982 (2000).